|Bid||141.16 x 1200|
|Ask||141.44 x 1000|
|Day's range||138.94 - 144.77|
|52-week range||119.01 - 497.49|
|Beta (5Y monthly)||1.70|
|PE ratio (TTM)||4.09|
|Earnings date||03 Aug 2022 - 08 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||220.00|
Moderna (NASDAQ: MRNA) shares have dropped 70% since their record high of more than $450 last August. The second reason has to do with Moderna specifically. The company's only commercialized product right now is the coronavirus vaccine, so investors worry about earnings if vaccine demand drops in a post-pandemic world.
For a stock to be a strong long-term buy, investors need to have confidence that its business will be able to grow indefinitely. Both Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) are examples of companies that continue to thrive today due to the pandemic with their highly successful COVID-19 vaccines generating billions in sales for their respective companies. COVID-19 revenue has resulted in surging revenue for Pfizer.
Moderna (NASDAQ: MRNA) and Repligen (NASDAQ: RGEN) are two companies that have seen their stock prices decrease even as they posted positive business results. While Moderna may have been known to some investors prior to the pandemic, the biotech company has become a household name as it was able to bring to market its highly successful vaccine for COVID-19. Prior to this, Moderna had nothing commercially available, so the sales growth over the past year-plus is from a base of zero revenue.